HITLAB and Versalie are proud to announce the winners of the HITLAB x Versalie Challenge, a groundbreaking competition dedicated to identifying digital health solutions that address the unique challenges faced by women during menopause.
HITLAB and Versalie proudly announce the top three finalists for their women’s health innovation challenge, a competition seeking innovative digital health solutions for menopause.
HITLAB is proud to announce the final winners of the 2024 Women’s Health Tech Challenge, a prestigious competition designed to recognize and reward innovators developing cutting-edge solutions that address critical unmet needs in women's health.
HITLAB is excited to announce the six finalists for the 2024 Women's Health Tech Challenge (WHTC), selected from a highly competitive pool of innovative digital health solutions aimed at addressing key issues in women's health.
HITLAB, a leading healthcare innovation lab, is thrilled to announce a collaboration with the Versalie™ brand to introduce a pioneering competition focused on women’s health, specifically targeting menopause. Building upon the launch of Versalie™1, a new digital-health brand focused on menopause, this Virtual Innovation Challenge aims to source cutting-edge solutions from small startups and entrepreneurs with Minimum Viable Products (MVPs).
HITLAB is excited to announce the launch of its Fall 2024 Breakthrough Alliance Challenge, a global competition designed to identify and support innovative digital health solutions. Applications will be opened until October 15, 2024.
HITLAB, a leading healthcare innovation lab, announces its partnership with Goodwin, a global law firm, to accelerate women's health technology advancements through the 2024 Women's Health Tech Challenge.
New York, NY, June 25, 2024 – HITLAB, a leader in health technology innovation, is thrilled to announce the launch of this year’s Women’s Health Tech Challenge.
The escalating prevalence of neurological disorders presents a growing challenge for healthcare, particularly in an aging population. Early diagnosis is crucial for effective treatment, but the mildness of initial symptoms and the absence of accessible monitoring tools can result in delays. Additionally, existing biomarkers lack objectivity, detailed insights, and reproducibility, impeding progress in diagnosis, treatment, and drug development.